TITLE:

Clinical characteristics and risk factors of ocular candidiasis.

AUTHOR(S):

Nagao, Miki; Saito, Takashi; Doi, Shoichi; Hotta, Gou;
Yamamoto, Masaki; Matsumura, Yasufumi; Matsushima, Aki;
Ito, Yutaka; Takakura, Shunji; Ichiyama, Satoshi

CITATION:

Nagao, Miki ...[et al]. Clinical characteristics and risk factors of ocular candidiasis..
Diagnostic microbiology and infectious disease 2012, 73(2): 149-152

ISSUE DATE:

2012-06

URL:

<http://hdl.handle.net/2433/156158>

RIGHT:

© 2012 Elsevier Inc.; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。

Clinical characteristics and risk factors of ocular candidiasis.

Miki Nagao^{1,2,3}, Takashi Saito^{1,2}, Shoichi Doi^{3,4}, Gou Hotta^{1,2},
Masaki Yamamoto^{1,2}, Yasufumi Matsumura^{1,2}, Aki Matsushima^{1,2},
Yutaka Ito^{1,5}, Shunji Takakura^{1,2}, Satoshi Ichiyama^{1,2}

1 Department of Infection Control and Prevention

Kyoto University Hospital, Kyoto, Japan

2 Department of Clinical Laboratory Medicine,

Kyoto University Graduate School of Medicine, Kyoto, Japan

3 Department of Infectious Disease

Kyoto Katsura Hospital, Kyoto, Japan

4 Hematology Division of Internal Medicine

Kyoto Katsura Hospital, Kyoto, Japan

20 5 Department of Respiratory Medicine

21 Kyoto University Graduate School of Medicine, Kyoto, Japan

22

23 **Running title**

24 Clinical characteristics of ocular candidiasis

25

26 **Corresponding author**

27 Miki Nagao

28 Department of Infection Control and Prevention

29 Kyoto University Hospital

30 Tel & Fax +81-75-751-4967

31 54 Shogoin-Kawahara-cho,

32 Sakyo-ku, Kyoto, 6068507 Japan

33 Email: mnagao@kuhp.kyoto-u.ac.jp

Abstract

Ocular candidiasis is a major complication of Candida bloodstream infection (BSI). This study was performed to reveal clinical characteristics of ocular candidiasis. Of the 220 patients with Candida BSI, 204 cases received ophthalmology consultations between January 2005 and December 2011 at two teaching hospitals. Fifty-four (26.5%) cases had findings consistent with the diagnosis of ocular candidiasis. Of these 54 cases, 43 (79.6%) were diagnosed within 7 days after a positive blood culture. Among ocular candidiasis cases, more cases were due to *Candida albicans* ($P = 0.034$ OR; 3.68 95% CI 1.11-12.2) and had higher beta-D-glucan values ($P = 0.001$ OR; 9.99 95% CI 2.60 - 21.3). We need to consider fundoscopic examination to be performed within first 7 days of therapy, especially for those patients who have *C. albicans* BSIs and higher beta-D-glucan values. Additionally, follow-up fundoscopic examination should be considered before stopping therapy for high-risk patients.

Introduction

Bloodstream infections (BSIs) caused by *Candida* species have been reported to be increasingly frequent in recent decades, possibly due to rapid changes in medical practice. *Candida* BSI can lead to hematogenous dissemination and metastatic ocular infection with potentially devastating consequences. Consequently, a rise in related mortality and prolonged hospitalisation has been reported [Edmond et al., 1999; Jarvis et al., 1995; Kao et al., 1999; Pfaller and Diekema, 2007; Rentz et al., 1998; Sheng et al., 2005; Wisplinghoff et al., 2004].

Normally, patients who have chorioretinitis alone are often asymptomatic and respond better to systemic antifungal therapy than those with vitreal involvement. However, in advanced stages, the intravitreal injection of an antifungal agent with or without vitrectomy is needed. Thus, it is very important for doctors to properly diagnose ocular candidiasis in the early stages of the infection.

In this study, patients with blood cultures positive for *Candida* BSIs were reviewed for the incidence and clinical characteristics of ocular candidiasis to reveal the risk factors of

71 ocular candidiasis.

72

73 **Materials and Methods**

74 **Study design**

75 This study was performed at two teaching hospitals in Kyoto,
76 Japan. Kyoto University Hospital (KUH) is a tertiary care
77 university hospital with 1240 beds, and Katsura Hospital is an
78 emergency hospital with 585 beds. Infectious disease physicians
79 perform proactive interventions for all patients with BSI in these
80 hospitals. In cases of *Candida* BSIs, catheter removal is
81 recommended, blood cultures are collected to confirm all negative
82 results, and finally, fundoscopy is performed by ophthalmologists
83 usually within first 7 days of therapy. *Candida* BSI was defined
84 by at least one positive blood culture for *Candida* species and a
85 clinical sign of infection (e.g., fever, hypotension or tachypnea).

86 Two hundred and twenty cases of *Candida* BSIs were
87 diagnosed in the two Kyoto teaching hospitals from January 2005
88 to December 2011. To assess the incidence and clinical
89 characteristics of patients with ocular involvement, we performed
90 medical chart reviews of the *Candida* BSI patients who had

91 consulted ophthalmologists. For the classification of ocular
92 candidiasis, we incorporated the criteria proposed by Oude Lashof
93 [Oude Lashof et al., 2011]. Proven ocular candidiasis was
94 defined as ocular lesions in combination with positive histology or
95 a positive culture of a vitreous aspirate. Probable *Candida*
96 endophthalmitis was defined as vitritis or fluffy lesions with
97 extensions into the vitreous humour. Probable *Candida*
98 chorioretinitis was defined as deep focal white infiltrates in the
99 retina. If signs of chorioretinitis were observed in patients with
100 an underlying systemic disease that reportedly exhibits similar
101 lesions (e.g., diabetes, hypertension or concomitant bacteremia),
102 these cases were classified as possible ocular candidiasis.

103 Clinical information acquired from medical charts included age,
104 sex, underlying diseases, receipt of corticosteroids or other
105 immunosuppressive agents during the previous 30 days, any
106 antimicrobial therapy during the previous 30 days, surgery
107 during the previous 30 days, time to first negative blood culture,
108 interval between blood culture and antifungal therapy, interval
109 between sign of infection and removal of the catheter or
110 antifungal agents, interval between positive fungal culture and

catheter removal, the specific fungal species, antifungal therapy and 30-day mortality. Digestive tract involvement included any gastrointestinal disorders such as malignancies of digestive tract and inflammatory bowel diseases. The (1,3)- β -D-glucan (BDG) test values that were taken within 3 days after positive blood cultures were also evaluated. At Katsura, the BDG values were determined using the Fungitec G test (Seikagaku Corporation, Tokyo, Japan). At KUH, the BDG values were determined using the WAKO β -glucan test (Wako Pure Chemical Industries, Tokyo, Japan). The results were analysed according to the manufacturer's instructions.

Statistical analysis

Categorical variables were compared using Fisher's exact test. Continuous variables were compared using the Kruskal-Wallis test or the Mann-Whitney U test. BDG values under the limit of detection were considered to be 0.0 pg/mL. Receiver-operating characteristic (ROC) curves for the BDG levels were constructed, and their optimal cut-off values were determined with the maximum Youden index. Potential factors associated with ocular candidiasis were examined by Cox proportional hazards

131 regression analysis. All covariates with a p -value of less than
132 0.10 on univariate analyses were subjected to further selection by
133 the above-mentioned multivariate analyses. The data were
134 analysed with PASW software version 18.0 (SPSS) for Microsoft
135 Windows. All P value tests were two-tailed, and $P < 0.05$ was
136 considered statistically significant.

137 138 **Results**

139 **Incidence**

140 Of the 220 patients with *Candida* BSI, 204 presented to
141 ophthalmologists for the diagnosis of ocular candidiasis were
142 included in this study. Six of the 16 *Candida* BSI patients who
143 did not consult ophthalmologists included critically ill patients
144 whose prognosis had been presumed to be very poor or who died
145 before the identification of positive fungal cultures.

146 Fifty-four (26.5%) of the 204 *Candida* BSI patients who were
147 evaluated by ophthalmologists had fundoscopic abnormalities
148 that met the criteria for ocular candidiasis. Among ocular
149 candidiasis cases, 10 were probable endophthalmitis, 24 were
150 probable chorioretinitis, and 20 cases were possible

151 chorioretinitis.

152 **Epidemiologic characteristics**

153 The baseline characteristics of the study population are shown in
154 Table 1. The groups with or without ocular involvement did not
155 differ with respect to age, sex, diabetes mellitus status, the use of
156 immunosuppressive agents or the use of systemic antibiotics
157 within the previous month, but more patients with ocular
158 involvement had malignancies. In addition, more patients with
159 ocular manifestations had digestive tract abnormalities (e.g.,
160 digestive tract surgery, inflammatory bowel syndromes,
161 malignancy of a digestive tract), whereas ocular candidiasis was
162 rare in the departments of Dermatology, Rheumatology and
163 Cardiovascular Surgery. Ocular candidiasis patients were
164 infected significantly more frequently with *Candida albicans* and
165 less often with *C. parapsilosis* than patients without retinal
166 lesions. The length of time to the first negative blood culture,
167 the time to catheter removal and the administration of antifungal
168 agents did not differ between groups.

169 **Timing of fundoscopic examination**

170 One hundred and eighty (88.2%) patients received fundoscopic

examination once and 24 patients received twice or more. Ocular abnormalities consistent with ocular candidiasis were diagnosed within 7 days after positive blood culture in 43 patients, whereas 11 patients were diagnosed as having ocular candidiasis more than 8 days later (Figure 1). Twenty-one (38.9%) patients were diagnosed within 3 days, and the average time from a positive blood culture to the diagnosis of ocular candidiasis was 5.5 days. The time to the first negative fungal culture was longer in the patients who were diagnosed with ocular candidiasis at the time of a second fundoscopy performed more than 8 days later after the positive fungal culture; all patients had malignancies, had diabetes mellitus or were being treated with immunosuppressive agents.

BDG values and ocular candidiasis

The diagnostic kit used for the measurement of BDG values differed between KUH and Katsura; therefore, we created ROC curves and determined that the appropriate cut-off values were 22.5 and 42.7 for KUH and Katsura, respectively. A case was defined as BDG-high if the BDG value was higher than the cut-off value. Using the cut-off value, more patients with ocular

candidiasis than patients with non-ocular candidiasis were grouped as BDG-high cases. There was no relationship between the BDG value and causative agents (data not shown).

Clinical outcome

Among 54 cases of ocular candidiasis, 42 patients completed antifungal therapy without any worsening of visual acuity, and 12 patients died before the completion of antifungal therapy.

Among the chorioretinitis cases, 33 out of 35 patients who provided a report indicated they had no ocular abnormalities.

Among the ocular candidiasis cases, micafungin was prescribed to 23 patients, and fluconazole was prescribed to 25 patients. In 16 of the 23 patients who received micafungin therapy, the antifungal treatment regimen was shifted to fluconazole or amphotericin-B after the diagnosis of ocular candidiasis.

The 30-day mortality rate of patients with ocular abnormalities was also higher, although these differences were not statistically significant.

Analysis of risk factors

Candida albicans as the etiological agent ($P = 0.034$ OR; 3.68 95% CI 1.11-12.2) and higher beta-D-glucan values ($P = 0.001$ OR; 9.99

211 95% CI 2.60 – 21.3) were statistically significant for the risk
212 factors of ocular candidiasis, as determined by multivariate
213 regression analysis (Table 2).

214

215 Discussion

216 This study investigated the incidence and clinical characteristics
217 of ocular candidiasis. According to previous studies, the
218 prevalence of ocular candidiasis is estimated to be between 1 -
219 45% [Rodrguez-Adria'n et al., 2003; Oude Lashof et al., 2011,
220 Parke et al., 1982; Brooks, 1989; Shah et al., 2008]. In this study,
221 ocular abnormalities occurred in 26% of 204 patients. It is likely
222 that patient selection led to the comparatively high prevalence of
223 ocular candidiasis. Among our patients, 50% had malignancies,
224 and more than 80% had predisposing risk factors such as
225 antibiotic exposure, diabetes mellitus or the use of
226 immunosuppressive therapy. Furthermore, many patients had
227 been admitted for gastrointestinal diseases. Malignancy and
228 gastrointestinal disease were statistically significant risk factors
229 for ocular candidiasis as determined by chi-squared tests,
230 although the statistical significance was not retained in the

multivariate regression model. Considering the pathogenesis of endogenous ocular candidiasis, physical mucosal damage and changes in normal flora induced by broad-spectrum antibiotics or chemotherapy may facilitate the occurrence of ocular involvement. Thus, the high prevalence of ocular candidiasis observed in this study may have been the result of the severely immunocompromised state of many patients.

Of all of the *Candida* species, *C. albicans* was observed to have the greatest propensity to cause ocular candidiasis. In contrast, *C. parapsilosis* was associated with ocular manifestations significantly less frequently. In this study, patients with ocular candidiasis were mostly infected with *C. albicans*, a finding that is consistent with prior reports (Donahue et al., 1994; Rodriguez-Adria'n et al., 2003; Oude Lashof et al., 2011, Parke et al., 1982; Brooks, 1989; Shah et al., 2008). Some of these cases occurred despite prompt catheter removal and the immediate administration of antifungal agents after the onset of *Candida* BSIs. These results suggest that fungal virulence as well as host and treatment factors may be involved in the pathogenesis of ocular candidiasis. It is likely that the high

prevalence of *C. albicans* may also have increased the rate of ocular candidiasis in this study.

Several studies revealed that the prospective evaluation of circulating BDG in high-risk patients generates positive results that are available before the culture results and can improve the diagnosis of invasive candidiasis (Koo et al., 2009; Acosta et al., 2011; Ostrosky-Zeichner et al., 2005). In this study, more patients with ocular candidiasis had higher BDG values, and BDG positivity had a significant relationship with the development of ocular candidiasis. However, there was no relationship between elevated BDG values and etiologic agents such as *C. albicans* or the prognosis of *Candida* BSIs (data not shown). Although the BDG values that reflect the burden of *Candida* species and the half-life are still unknown, when higher BDG values are present, ocular candidiasis may have already occurred in these patients, even if they are asymptomatic.

Despite the high prevalence of ocular candidiasis, periodic ophthalmologic examinations are rarely performed in patients susceptible to opportunistic infection. According to the IDSA guidelines for invasive candidiasis, ophthalmologists should

investigate each patient for the presence of ocular candidiasis (Pappas et al., 2009), but the optimal timing for this evaluation has not been established. Previous studies have advised an interval of < 14 days between the start of treatment and the first retinal abnormality, an interval that is consistent with candidal chorioretinitis (Rodrguez-Adria'n et al., 2003; Krishna et al., 2000). Although the optimal treatment for endogenous ocular candidiasis has not been clearly established yet, fluconazole and voriconazole appear to be the most effective (pappas et al., 2009; Khan et al., 2007). In our study, 80% of cases were diagnosed within 7 days, and the antifungal agents were changed from micafungin to azoles or amphotericin in 16 of the 42 ocular candidiasis cases. If fundoscopy was performed later, the opportunity for the earlier administration of potentially more optimal antifungal agents might have been missed. In our study, more than 80% of the ocular candidiasis cases were chorioretinitis, which usually does not require surgical interventions. Many patients completed the course of antifungal therapy without any visual disturbance. We speculate that earlier diagnosis and treatment resulted in the improved prognosis regarding visual

acuity. On the other hand, some ocular candidiasis cases were diagnosed by a second fundoscopic examination more than 8 days later. Ideally, when we consider a strategy based on the fact that earlier diagnosis yields a better prognosis, fundoscopic examination should be performed within first 7 days of antifungal therapy, especially in those with *C. albicans* BSIs and higher BDG values. In addition, follow-up fundoscopic examination should also be considered in severely immunosuppressed patients, even if the first fundoscopic examination yielded negative results.

Study limitations

This study has several limitations, including the fact that most of the patients without ocular candidiasis were not re-examined serially. Conceivably, the disseminated fungal lesions could have arisen in healthy eyes after the initial exam and therefore may have been missed in some cases. Second, approximately 7.2% of the *Candida* BSI patients did not consult ophthalmologists for their underlying conditions. During discussion with those patients about the risk factors for ocular candidiasis, fundoscopy may have been indicated but not performed in some cases.

311 Thirdly, we included the possible cases of ocular candidiasis who
312 had severe underlying diseases in this study. The prevalence
313 rate of ocular candidiasis might have been much lower than
314 reported here.

315 **Transparency Declaration**

316 This work was partly supported by grant H21-Shinko-Ippan-009
317 and H23-Shinkou-Ippan-018 from the Ministry of Health, Labor,
318 and Welfare of Japan. Some of the results were generated
319 during routine diagnostic activities. No commercial
320 relationships or potential conflicts of interest exist.

321

References

1. Acosta J, Catalan M, Del Palacio-Perez-MEdel A, Montejo JC, De-La-Cruz-Bertolo J, Moraques MD, Ponton J, Finkelman MA, Del Placio A (2011) Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)- β -D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease *Eur J Clin Microbiol Infect Dis* Aug 3. [Epub ahead of print]
2. Brooks RG (1989) Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. *Arch Intern Med* 149:2226–8.
3. Donahue SP, Greven CM, Zuravleff JJ, Eller AW, Nguyen MH, Peacock JE Jr, Wagener MW, Yu VL (1994) Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. *Ophthalmology* 101:1302–9.
4. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial blood stream infections in United States hospitals: a three-year analysis. *Clin Infect Dis* 29: 239–44.

- 342 5. Jarvis WR (1995) Epidemiology of nosocomial fungal
343 infections, with emphasis on *Candida* species *Clin Infect Dis*
344 20:1526–30.
- 345 6. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA,
346 Stephens DS, Baughman ES, Reingold AL, Rothrock GA,
347 Pfaller MA, Pinner RW, Haijeh RA (1999) The epidemiology of
348 candidemia in two United States cities: results of a
349 population-based active surveillance *Clin Infect Dis*
350 29:1164–70.
- 351 7. Khan FA, Slain D, Khakoo RA (2007) *Candida*
352 endophthalmitis: Focus on current and future antifungal
353 treatment options. *Pharmacotherapy* 27:1711–21.
- 354 8. Koo S, Bryar JM, Page JH, Baden LR, Marty FM (2009)
355 Diagnostic performance of the (1→3)- β -D-Glucan assay for
356 invasive fungal disease. *Clin Infect Dis* 49:1650-9.
- 357 9. Krishna R, Amuh D, Lowder CY, Gordon SM, Adal KA, Hall G
358 (2000) Should all patients with candidaemia have an
359 ophthalmic examination to rule out ocular candidiasis? *Eye*
360 14:30–34.
- 361 10. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J,

- 362 Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R,
363 Tamura H, Finkelman MA, Rex JH (2005) Multicenter clinical
364 evaluation of (1→3)-β-D-Glucan assay as an aid to diagnosis of
365 fungal infections in humans. *Clin Infect Dis* 41:654-9.
- 366 11. Oude Lashof AM, Rothova A, Sobel JD Ruhnke M, Pappas PG,
367 Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ
368 (2011) Ocular manifestations of candidemia. *Clin Infect Dis*
369 53:262-8.
- 370 12. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr,
371 Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg
372 BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel
373 JD; Infectious Diseases Society of America (2009) Clinical
374 practice guidelines for the management of candidiasis: 2009
375 update by the Infectious Diseases Society of America. *Clin*
376 *Infect Dis* 48:503–35.
- 377 13. Parke DW 2nd, Jones DB, Gentry LO (1982) Endogenous
378 endophthalmitis among patients with candidemia.
379 *Ophthalmology* 89:789–96.
- 380 14. Pfaller MA, and Diekema DJ (2007) Epidemiology of invasive
381 candidiasis: a persistent public health problem *Clin Microbiol*

- 382 *Rev* 20:133–163.
- 383 15. Rentz AM, Halpern MT, Bowden R (1998) The impact of
- 384 candidemia on length of hospital stay, outcome, and overall
- 385 cost of illness. *Clin Infect Dis* 27:781-788.
- 386 16. Rodriguez-Adria'n LJ, King RT, Tamayo-Derat LG, Miller JW,
- 387 Garcia CA, Rex JH (2003) Retinal lesions as clues to
- 388 disseminated bacterial and candidal infections: Frequency,
- 389 natural history, and etiology. *Medicine* (Baltimore)
- 390 82:187–202.
- 391 17. Shah CP, Mckey J, Spirn MJ Maquire J (2008) Ocular
- 392 candidiasis: a review. *Br J Ophthalmol* 92:466-468.
- 393 18. Sheng WH, Wang JT, Lu DC, Chie WC, Chen YC, Chang SC
- 394 (2005) Comparative impact of hospital stay and outcome
- 395 between community hospitals and medical centres. *J Hosp*
- 396 *Infect* 59:205-214.
- 397 19. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
- 398 and Edmond MB (2004) Nosocomial bloodstream infections in
- 399 US hospitals: analysis of 24,179 cases from prospective
- 400 nationwide surveillance study. *Clin Infect Dis* 39:309-317.

401

402 Figure 1 Cumulative incidence of ocular candidiasis

403

404 Ocular candidiasis was diagnosed within 7 days after positive
405 blood culture in 43 patients, whereas 11 patients were diagnosed
406 with ocular candidiasis more than 8 days later.

407

Figure 1

1 Table 1 Clinical characteristics of the study patients

	Ocular		Non-ocular		<i>P</i>
	candidiasis	(%)	candidiasis	(%)	
	(N=54)		(N=150)		
Age	62.8 ± 18.9		63.14 ± 19.8		0.923
Male	28	51.9%	80	53.3%	0.875
Malignancy	41	75.9%	60	40.0%	<0.001
Diabetes mellitus	12	28.6%	22	17.3%	0.210
Digestive tract involvement	35	68.6%	61	41.5%	0.001
Immunosuppressive agent	20	37.0%	32	21.3%	0.083
Antibiotic within one month	46	86.8%	112	74.7%	0.083
Surgery within one month	17	31.5%	46	30.7%	0.911
<i>C. parapsilosis</i>	3	5.6%	35	23.3%	0.002
<i>C. albicans</i>	40	74.1%	67	44.7%	<0.001
<i>C. glabrata</i>	5	9.3%	19	12.7%	0.626
<i>C. tropicalis</i>	5	9.3%	18	12.0%	0.862
High beta-D-glucan (N=88)	29	74.4%	31	34.4%	<0.001
Time to first negative blood culture, mean, range (days)	5.52 ± 4.04, 1-14		5.32 ± 3.40, 1-27		0.787
Blood culture to antifungal agent, mean, range (days)	1.82 ± 1.37, 1-5		2.34 ± 2.81, 1-5		0.117
First sign of infection to removal of the catheter,	1.52 ± 2.30, 1-12		1.56 ± 2.17, 1-11		0.920

mean, range (days)					
Sign of infection to antifungal agents, mean, range (days)	2.28 ±	2.36 ± 2.53,			0.872
	3.17, 1-8	1-9			
Interval between positive fungal culture and catheter removal, mean, range (days)	1.00 ±	0.72 ± 1.82,			0.647
	3.99, 1-3	1-3			
30-day mortality	14	25.9%	28	18.7%	0.326

Table 2 Results of multivariate regression analysis of factors associated with ocular candidiasis

	<i>P</i> value	Exp(B)	95% CI
(1,3)- β -D-glucan high	0.001	9.99	2.60-21.3
<i>C. albicans</i>	0.034	3.68	1.11-12.2
Digestive tract involvement	0.290		
Malignancy	0.714		
Immunosuppressive agent	0.625		
Antibiotic within one month	0.483		